Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.61 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 2/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | IL1RN | P18510 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824408 | 0.97 | ERAP2 (0.64) | ERAP2LNPEPERAP1TSHRNPY4R | |
| SCHEMBL27824405 | 0.97 | ERAP2 (0.64) | ERAP2LNPEPERAP1TSHRNPY4R | |
| SCHEMBL11359300 | 0.92 | TSHR (0.67) | ERAP2LNPEPERAP1TSHRMDM4 | |
| SCHEMBL11597665 | 0.92 | TSHR (0.67) | ERAP2LNPEPERAP1TSHRMDM4 | |
| SCHEMBL10394119 | 0.92 | TSHR (0.67) | ERAP2LNPEPERAP1TSHRMDM4 | |
| Bromide SCHEMBL11599446 | 0.91 | TSHR (0.65) | ERAP2LNPEPERAP1TSHRMDM4 | |
| Hydrochloric Acid SCHEMBL11581442 | 0.91 | TSHR (0.65) | ERAP2LNPEPERAP1TSHRMDM4 | |
| Bromide SCHEMBL11599445 | 0.91 | TSHR (0.65) | ERAP2LNPEPERAP1TSHRMDM4 | |
| Hydrochloric Acid SCHEMBL11581436 | 0.91 | TSHR (0.65) | ERAP2LNPEPERAP1TSHRMDM4 | |
| SCHEMBL31754289 | 0.90 | ERAP2 (0.57) | ERAP2LNPEPERAP1TSHRNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071134-B2 | treating subjects having conditions related to angiogenesis; thyroid hormone, thyroid hormone analog, or polymeric forms thereof | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20080124280-A1 | Thyroid Hormone Analogs and Methods of Use | NANOPHARMACEUTICALS LLC | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124280-A1 | Thyroid Hormone Analogs and Methods of Use | TSHR, TPO, TRHR | ERAP2 1753/4885LNPEP 478/4885ERAP1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.